Bain Capital Life Sciences Investors
Latest statistics and disclosures from Bain Capital Life Sciences Investors's latest quarterly 13F-HR filing:
- Top 5 stock holdings are NAMS, NUVL, DNTH, IRON, Kyverna Therapeutics, and represent 56.31% of Bain Capital Life Sciences Investors's stock portfolio.
- Added to shares of these 8 stocks: DNTH (+$90M), Kyverna Therapeutics (+$79M), MDGL (+$53M), ANNX (+$22M), SLDB (+$12M), SYRS, SVRA, XFOR.
- Started 3 new stock positions in DNTH, MDGL, Kyverna Therapeutics.
- Reduced shares in these 10 stocks: SWTX (-$71M), NUVL (-$66M), CRNX (-$38M), PHVS (-$34M), NTRA (-$31M), Eqrx (-$22M), Cymabay Therapeutics (-$14M), DVAX (-$14M), NRIX (-$10M), ARQT (-$9.8M).
- Sold out of its positions in CARA, CRNX, Cymabay Therapeutics, DVAX, Eqrx, NTRA, SWTX, TSVT.
- Bain Capital Life Sciences Investors was a net seller of stock by $-68M.
- Bain Capital Life Sciences Investors has $1.2B in assets under management (AUM), dropping by 39.15%.
- Central Index Key (CIK): 0001703031
Tip: Access up to 7 years of quarterly data
Positions held by Bain Capital Life Sciences Investors consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Bain Capital Life Sciences Investors
Bain Capital Life Sciences Investors holds 26 positions in its portfolio as reported in the March 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 19.9 | $248M | 11M | 23.65 |
|
|
| Nuvalent Inc-a (NUVL) | 16.3 | $203M | -24% | 2.7M | 75.09 |
|
| Dianthus Therapeutics (DNTH) | 7.2 | $90M | NEW | 3.0M | 30.00 |
|
| Disc Medicine (IRON) | 6.6 | $82M | 1.3M | 62.26 |
|
|
| Kyverna Therapeutics | 6.3 | $79M | NEW | 3.2M | 24.84 |
|
| Pharvaris N V (PHVS) | 6.1 | $76M | -30% | 3.3M | 23.11 |
|
| Savara (SVRA) | 5.8 | $73M | +2% | 15M | 4.98 |
|
| Annexon (ANNX) | 5.0 | $62M | +52% | 8.7M | 7.17 |
|
| Solid Biosciences Com New (SLDB) | 4.3 | $54M | +28% | 4.0M | 13.32 |
|
| Madrigal Pharmaceuticals (MDGL) | 4.2 | $53M | NEW | 197k | 267.04 |
|
| Mersana Therapeutics (MRSN) | 3.1 | $39M | 8.7M | 4.48 |
|
|
| Cabaletta Bio (CABA) | 2.2 | $28M | -19% | 1.6M | 17.06 |
|
| X4 Pharmaceuticals (XFOR) | 1.9 | $24M | +5% | 17M | 1.39 |
|
| Tango Therapeutics (TNGX) | 1.8 | $23M | 2.9M | 7.94 |
|
|
| Arcutis Biotherapeutics (ARQT) | 1.6 | $20M | -32% | 2.0M | 9.91 |
|
| Nurix Therapeutics (NRIX) | 1.3 | $17M | -37% | 1.1M | 14.70 |
|
| Syros Pharmaceuticals Com New (SYRS) | 1.2 | $15M | +29% | 2.7M | 5.35 |
|
| Marinus Pharmaceuticals Com New (MRNS) | 1.0 | $13M | -2% | 1.4M | 9.04 |
|
| Atea Pharmaceuticals (AVIR) | 0.8 | $10M | 2.5M | 4.04 |
|
|
| C4 Therapeutics Com Stk (CCCC) | 0.7 | $9.3M | -30% | 1.1M | 8.17 |
|
| Rapid Micro Biosystems Class A Com (RPID) | 0.7 | $8.2M | 8.4M | 0.97 |
|
|
| Adagio Therapeutics (IVVD) | 0.6 | $8.0M | -7% | 1.8M | 4.44 |
|
| Nautilus Biotechnology (NAUT) | 0.5 | $5.9M | 2.0M | 2.94 |
|
|
| Aclaris Therapeutics (ACRS) | 0.3 | $3.7M | -11% | 3.0M | 1.24 |
|
| Xilio Therapeutics (XLO) | 0.2 | $3.0M | 2.8M | 1.08 |
|
|
| Newamsterdam Pharma Company *w Exp 99/99/999 (NAMSW) | 0.1 | $1.1M | 100k | 11.04 |
|
Past Filings by Bain Capital Life Sciences Investors
SEC 13F filings are viewable for Bain Capital Life Sciences Investors going back to 2017
- Bain Capital Life Sciences Investors 2024 Q1 filed May 15, 2024
- Bain Capital Life Sciences Investors 2023 Q3 filed Nov. 14, 2023
- Bain Capital Life Sciences Investors 2023 Q2 filed Aug. 14, 2023
- Bain Capital Life Sciences Investors 2023 Q1 filed May 15, 2023
- Bain Capital Life Sciences Investors 2022 Q4 filed Feb. 14, 2023
- Bain Capital Life Sciences Investors 2022 Q3 filed Nov. 14, 2022
- Bain Capital Life Sciences Investors 2022 Q2 filed Aug. 15, 2022
- Bain Capital Life Sciences Investors 2022 Q1 filed May 16, 2022
- Bain Capital Life Sciences Investors 2021 Q4 filed Feb. 14, 2022
- Bain Capital Life Sciences Investors 2021 Q3 filed Nov. 15, 2021
- Bain Capital Life Sciences Investors 2021 Q2 filed Aug. 16, 2021
- Bain Capital Life Sciences Investors 2021 Q1 filed May 17, 2021
- Bain Capital Life Sciences Investors 2020 Q4 filed Feb. 16, 2021
- Bain Capital Life Sciences Investors 2020 Q3 filed Nov. 16, 2020
- Bain Capital Life Sciences Investors 2020 Q2 filed Aug. 14, 2020
- Bain Capital Life Sciences Investors 2020 Q1 filed May 15, 2020